Inhibitor specificity via protein dynamics: insights from the design of antibacterial agents targeted against thymidylate synthase.

Structure-based drug design of species-specific inhibitors generally exploits structural differences in proteins from different organisms. Here, we demonstrate how achieving specificity can be aided by targeting differences in the dynamics of proteins. Thymidylate synthase (TS) is a good target for anticancer agents and a potential target for antibacterial agents. Most inhibitors are folate-analogs that bind at the folate binding site and are not species specific. In contrast, alpha156 is not a folate-analog and is specific for bacterial TS; it has been shown crystallographically to bind in a nonconserved binding site. Docking calculations and crystal structure-based estimation of the essential dynamics of TSs from five different species show that differences in the dynamics of TSs make the active site more accessible to alpha156 in the prokaryotic than in the eukaryotic TSs and thereby enhance the specificity of alpha156.

[1]  H. Wolfson,et al.  Multiple diverse ligands binding at a single protein site : A matter of pre-existing populations , 2001 .

[2]  G. Maley,et al.  Crystal structure of a deletion mutant of human thymidylate synthase Δ (7–29) and its ternary complex with Tomudex and dUMP , 2001, Protein science : a publication of the Protein Society.

[3]  R. Stroud,et al.  Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. , 1999, Journal of medicinal chemistry.

[4]  R. Poorman,et al.  Dynamics of stromelysin/inhibitor interactions studied by 15N NMR relaxation measurements: Comparison of ligand binding to the S1-S3 and S′1-S′3 subsites , 1999, Journal of biomolecular NMR.

[5]  I. Kuntz,et al.  Structure-based discovery of inhibitors of thymidylate synthase. , 1993, Science.

[6]  D. Hanahan.  Studies on transformation of Escherichia coli with plasmids. , 1983, Journal of molecular biology.

[7]  R. Stroud,et al.  Conformational dynamics along an enzymatic reaction pathway: thymidylate synthase, "the movie". , 2003, Biochemistry.

[8]  J. Mccammon,et al.  Rate theory for gated diffusion-influenced ligand binding to proteins , 1982 .

[9]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[10]  G. Vriend,et al.  Prediction of protein conformational freedom from distance constraints , 1997, Proteins.

[11]  D. Santi,et al.  The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.

[12]  J. Mccammon,et al.  Conformation gating as a mechanism for enzyme specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Santi,et al.  Isolation and expression of the Pneumocystis carinii thymidylate synthase gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Berendsen,et al.  Essential dynamics of proteins , 1993, Proteins.

[15]  R. Stroud,et al.  Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase. , 2001, Chemistry & biology.

[16]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.

[17]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[18]  Structure-based design of inhibitors specific for bacterial thymidylate synthase. , 1999, Biochemistry.

[19]  D. Herries.  Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems: By Irwin H. Segel. John Wiley & Sons, 1975. pp xxii + 957. Boards, £15.00 , 1976 .

[20]  H. Kubinyi.  Structure-based design of enzyme inhibitors and receptor ligands. , 1998, Current opinion in drug discovery & development.

[21]  G. Maley,et al.  Properties of a defined mutant of Escherichia coli thymidylate synthase. , 1988, The Journal of biological chemistry.

[22]  R. Stroud,et al.  The structural mechanism for half-the-sites reactivity in an enzyme, thymidylate synthase, involves a relay of changes between subunits. , 1999, Biochemistry.

[23]  R M Stroud,et al.  Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking. , 2001, Chemistry & biology.

[24]  David A. Matthews,et al.  Structure of and kinetic channelling in bifunctional dihydrofolate reductase–thymidylate synthase , 1994, Nature Structural Biology.

[25]  D. Santi,et al.  Purification and characterization of recombinant Pneumocystis carinii thymidylate synthase. , 1991, Protein expression and purification.

[26]  Leslie A. Kuhn,et al.  Database Screening for HIV Protease Ligands: The Influence of Binding-Site Conformation and Representation on Ligand Selectivity , 1999, ISMB.

[27]  Heather A Carlson,et al.  Protein flexibility is an important component of structure-based drug discovery. , 2002, Current pharmaceutical design.

[28]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[29]  W. Sirawaraporn,et al.  Heterologous expression of the bifunctional thymidylate synthase-dihydrofolate reductase from Leishmania major. , 1988, Biochemistry.

[30]  R M Stroud,et al.  Atomic structure of thymidylate synthase: target for rational drug design. , 1987, Science.

[31]  D. Santi,et al.  Kinetics and mechanism of interaction of 10-propargyl-5,8-dideazafolate with thymidylate synthase. , 1986, Journal of medicinal chemistry.

[32]  R M Stroud,et al.  Refined structures of substrate-bound and phosphate-bound thymidylate synthase from Lactobacillus casei. , 1993, Journal of molecular biology.

[33]  D. Santi,et al.  Purification methods for recombinant Lactobacillus casei thymidylate synthase and mutants: a general, automated procedure. , 1992, Protein expression and purification.

[34]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[35]  Daniel A. Gschwend,et al.  Specificity in structure‐based drug design: Identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase , 1997, Proteins.

[36]  R. Stroud,et al.  The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition. , 1996, Structure.

[37]  Maria Paola Costi,et al.  Structure-based studies on species-specific inhibition of thymidylate synthase. , 2002, Biochimica et biophysica acta.

[38]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[39]  R. Stroud,et al.  Plastic adaptation toward mutations in proteins: Structural comparison of thymidylate synthases , 1990, Proteins.

[40]  L. Lebioda,et al.  Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. , 2001, Biochemistry.

[41]  D. Agard,et al.  Enzyme specificity under dynamic control II: Principal component analysis of α‐lytic protease using global and local solvent boundary conditions , 2001, Protein science : a publication of the Protein Society.

[42]  Dan S. Tawfik,et al.  Antibody Multispecificity Mediated by Conformational Diversity , 2003, Science.

[43]  R. Stroud,et al.  Structure, multiple site binding, and segmental accommodation in thymidylate synthase on binding dUMP and an anti-folate. , 1990 .